Staar Surgical
This article was originally published in The Gray Sheet
Executive Summary
Expansion of Implantable Contact Lens (ICL) clinical trials for hyperopia is approved by FDA May 26, the company reports, allowing Monrovia, California-based Staar to begin Phase III trials for the device. Approval of the protocol will allow the firm to expand the study to include patients with as little as 1.5 diopters of hyperopia and reduce the waiting time for patients to receive an ICL in the second eye from six months to 45 days. Additionally, the firm will be allowed to implant an additional 278 ICLs and expand from 14 to 18 sites nationwide
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.